secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001140361-25-004971
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin reports 68.1% reduction in new varices with belapectin in U.S. patients from NAVIGATE trial
--------------------------------------------------------------------------------

- Per-protocol U.S. patients (n=186): 68.1% reduction in new varices with belapectin 2 mg vs placebo (p=0.02).
- New prevalence estimate: ~3 million U.S. adults with MASH cirrhosis and clinically significant portal hypertension.
- Top-line composite endpoint missed statistical significance in ITT (N=355); completer analysis had 49.3% reduction (p=0.04 revised).
- Full analysis ongoing; additional 36-month data expected by end of Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125004971/0001140361-25-004971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125004971/ny20043588x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-004971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer